According to Inhalation Sciences (ISAB), Akari Therapeutics has chosen ISAB’s CRO, Inhalation Research Services, to conduct a pharmacokinetic study of Akari’s Nomacopan, a C5 and LTB4 inhibitor that the company is evaluating as an inhaled therapy for the treatment of exacerbations in COPD and asthma. The PK study will be conducted using an isolated perfused lung (IPL) method developed for use with ISAB’s PreciseInhale aerosol generation system.
Akari Therapeutics CEO Clive Richardson commented, “We’re pleased to be working with Inhalation Research Services. Their extensive experience, combined with the accuracy of this technology, inspires confidence and we believe will help us refine our inhaled treatment strategy with Nomacopan.”
ISAB CEO Manoush Masarrat said, “We are delighted to be working with this project. New biologic therapies are an exciting and thriving area of research within inhalation. Our work with Akari Therapeutics underlines how well we can support companies in this – with services like IPL and our XposeALI system, which connects the PreciseInhale to measure the effect of inhaled proteins on cell layers. This is an exciting project and we’re pleased to be moving ahead with it.”
Read the Inhalation Sciences press release.
